The CAT is a short, simple and validated assessment,
which measures the impact of COPD on a patient’s life in an objective
manner1.
The CAT was developed to facilitate a meaningful discussion between
healthcare professionals and patients and provide a reliable measure
of the impact of COPD on a patient’s life. It’s hoped that, as a result
of this enhanced communication, the CAT will improve the management
of COPD and patients’ quality of life.
Validation
The CAT has been developed using modern psychometric and statistical
techniques, which ensure that items included in the CAT contribute
to the measurement of the impact of COPD on a patient’s life in an
accurate and reliable manner. These techniques also ensure that the
CAT is useful for men and women alike, with different degrees of COPD
disease severity and in different parts of the world1.
Reference
Page Last Updated: April 25, 2012
COPD Assessment Test and CAT logo is a trade mark of the GlaxoSmithKline group of companies.
©2009 GlaxoSmithKilne group of companies. All rights reserved.
